Skip to Content

Join the 'Seebri Neohaler' group to help and get support from people like you.

Seebri Neohaler News

FDA Approves Seebri Neohaler (glycopyrrolate) for COPD

Posted 4 Nov 2015 by

EAST HANOVER, N.J., Oct. 29, 2015 Novartis announced today that the US Food and Drug Administration (FDA) has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 mcg as a stand-alone monotherapy for COPD. Novartis expects that Seebri Neohaler will be available in the first quarter of 2016. Seebri is delivered via the low resistance Neohaler inhaler, which makes it suitable for patients with different severities of airflow limitation. About Seebri Neohaler Seebri Neohaler, previously known as NVA237, is a twice-daily long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. Glycopyrrolate (also known as glycopyrronium bromide) was exclusively licensed to Novartis in April 2005 by Vectura and its co-development partner Sosei. About Novartis Respiratory ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Glycopyrrolate, Seebri Neohaler

Ask a Question

Further Information

Related Condition Support Groups

Chronic Obstructive Pulmonary Disease, Maintenance

Seebri Neohaler Patient Information at